Context Therapeutics Plunges 30% After-Hours on Wider Loss and Pipeline Shake-Up
CNTX is trading near its 52-week low of $0.545 (12% below the low).
Summary
Context Therapeutics reported a Q2 net loss of $14.6 million, up from $8.8 million a year ago, driven by a $6.5 million charge and higher R&D spending. The company is discontinuing its CT-95 program to focus on CTIM-76 and CT-202, with initial clinical data now expected in Q2 2027 and a Phase 1 start for CT-202 in Q3 2026. Cash of $43 million is projected to fund operations into Q4 2027. The stock fell 30.45% after hours to $0.48, erasing the day's 11% gain. This follows a Nasdaq delisting notice last week for trading below $1.00, adding pressure to the pipeline refocus. A $5 price target was noted.
At the time of this announcement, CNTX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.7M. The 52-week trading range was $0.55 to $3.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.